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MegalinThrough binding to parathyroid hormone (PTH), PTH1R interacts with kidney-speciﬁc scaffold proteins,
including the sodium hydrogen exchanger regulatory factors 1 and 2 (NHERFs), and ezrin. To facilitate in
vivo localization, tetramethylrhodamine-labeled PTH (PTH-TMR) was used as a ﬂuorescent probe. In mice,
PTH-TMR localizes to luminal surfaces of tubular S1 segments that overlap PTH1R immunostaining, but
does not directly overlap with megalin-speciﬁc antibodies. PTH-TMR staining directly overlaps with Npt2a
in nascent, endocytic vesicles, marking the location of transporter regulation. PKA substrate antibodies dis-
play marked staining increases in segments labeled with PTH-TMR, demonstrating a functional effect. In
the presence of secondary hyperparathyroidism, PTH-TMR staining is markedly reduced and shifts to
co-localizing with megalin. At 15 min post-injection, PTH-TMR-labeled vesicles do not co-localize with either
NHERF or ezrin, suggesting PTH1R dissociation from the scaffold complex. At the 5 min time point, PTH-TMR
stains the base of microvilli where it localizes with both NHERF2 and ezrin, and only partially with NHERF1.
Strikingly, the bulk of ezrin protein becomes undetectable with the polyclonal, CS3145 antibody, revealing a
PTH-induced conformational change in the scaffold. A second ezrin antibody (3C12) is capable of detecting
the altered ezrin protein. The CS3145 antibody only binds to the active form of ezrin and fails to recognize
the inactive form, while the 3C12 reagent can detect either active or inactive ezrin. Here we show that the
PTH1R is part of the ezrin scaffold complex and that acute actions of PTH suggest a rapid inactivation of
ezrin in a spatially deﬁned manner.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The parathyroid hormone 1 receptor (PTH1R) directs a remarkably
complex set of physiological processes [1]. At the root of this complexity
is that two physiologically distinct peptide hormones activate the
PTH1R, namely parathyroid hormone (PTH) and parathyroid hormone
related protein (PTHrP). PTH, an endocrine factor, regulates mineral
ion homeostasis by targeting bone and kidney. Conversely, PTHrP is
an auto/paracrine factor that plays an important role during theparathyroid hormone-related
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rights reserved.development of many tissues [2]. The paradigm of only one receptor
binding to two hormones combined with these diverse physiological
responses likely requires secondary levels of protein–protein interac-
tions beyond the receptor and ligand. Consistent with this paradigm,
the PTH1R not only couples to every major heterotrimeric G protein
sub-family, including Gs, Gq/11, Gi and G12/13, but also direct interactions
with many non-G proteins have been described [3].
As a primary regulator of mineral ion homeostasis, PTH directly
targets the proximal convoluted tubules (PCT) of the kidney where
it mediates the down-regulation of sodium-dependent phosphate
co-transporters, NPT2a, NPT2c and PiT2, and enhances the expression
of 25-hydroxyvitamin D3 1α-hydroxylase, leading to an increase in
the bioactive form of vitamin D. Considering that PTH is a blood-borne
endocrine factor, one would assume that the PTH1R would reside on
basolateral surfaces of the proximal tubule. However, several groups
have reported that the PTH1R is both physically and functionally locat-
ed on the apical membranes of this target tissue inmouse kidney [4–7],
characteristics that have also been demonstrated in well-polarized
kidney cell models [8–10]. Notably, physical and functional interactions
between the PTH1R and prominent brush-border-speciﬁc scaffold pro-
teins have been described.
2244 J. Guo et al. / Biochimica et Biophysica Acta 1823 (2012) 2243–2253The carboxy-terminal tail of the PTH1R, which is located in the cyto-
plasm, contains two independent interaction domains that mediate
binding to sodium–hydrogen exchange factors (NHERFs) and ezrin.NHERF1 and NHERF2 possess two PDZ interaction modules that direct
binding to the C-terminal four amino acids of the PTH1R (ETVM)
[11,12]. Using various cell models, NHERFs promote PTH-mediated
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membrane, interactions that inﬂuence receptor mobility and internali-
zation [13–16]. NHERFs contain a C-terminal domain that also directs
interactions with ERM (ezrin, radixin, moesin) proteins, such as ezrin.
Ezrin is a membrane-actin cytoskeleton cross-linking scaffold protein,
interactions mediated by an amino-terminal FERM domain and a con-
served actin-binding module, respectively. Within the juxtamembrane
region of the PTH1RC-terminal, a lysine-arginine-lysine (KRK)motif di-
rects interactions with the FERM domain of ezrin in vitro and in cells
[10]. Consistent with the binding mechanisms of other membrane pro-
teins, such as CD44 [17], the PTH1R C-tail binds to the FERM domain of
ezrin at a site that is mutually exclusive from the binding groove occu-
pied by the C-terminus of NHERF1. At least in vitro, therefore, the
PTH1R, ezrin and NHERF1 are capable of forming a ternary complex
[10].
As noted above, the PTH1R appears to be predominantly expressed
on apical surfaces of the proximal convoluted tubule (PCT) of the kid-
ney. Importantly, both NHERF1 and ezrin are abundantly expressed
and NHERF2 to a lesser extent on the apical, brush-border of the PCT
[18,19]. Consistent with the in vivo expression patterns, ezrin, NHERF1
and the PTH1R readily co-localize to the apical microvilli of the
LLC-PK1 cell line, a well-polarized kidney cell model [10]. In LLC-PK1
cells, apical and basolateral PTH1R sub-populations exist at a 3 to 1
ratio, respectively. Notably, apical expression of the PTH1R is dependent
upon the active form of ezrin [10]. The focus of the current research is to
analyze the localization patterns of the PTH1R and the ezrin-NHERF
scaffold complex in the PCT of the mouse kidney. Due to the poor qual-
ity of PTH1R antibodies, receptor localization is facilitated by the use of a
ﬂuorescently labeled PTH ligand. Here we show that upon subcutane-
ous injection of hormone, the ligand-bound PTH1R is spatially localized
to the brush-border of the PCT where it directs Npt2a endocytosis,
enhances PKA activity and likely induces dynamic regulation of the
ezrin-NHERF scaffold complex.
2. Materials and methods
2.1. Reagents
Human parathyroid hormone (1–34) was synthesized at the MGH
Biopolymer Core facility, a gift from Dr. Gardella (Massachusetts
General Hospital). The primary amine on the side chain of lysine 13
was labeled with tetramethylrhodamine to generate the ﬂuorescent
ligand probe (PTH-TMR). The polyclonal antibody to the PTH1R was
from Covance (Princeton Township, NJ). The polyclonal ezrin anti-
body (CS3145) and the PKA substrate antibody (CS9621) were pur-
chased from Cell Signaling Technology (Beverly, MA). The 3C12
monoclonal ezrin antibody, Alexa ﬂuor 488-labeled phalloidin, and
secondary antibodies labeled with Alexa ﬂuor 488 and 546were pur-
chased from Life Technologies Corporation (Carlsbad, CA). Primary
antibodies to panGβ (sc-378), Gαs (sc-383), Gαi3 (sc-262), Gαq/11
(sc-392) and PLCβ1 (sc-205) and HRP-labeled secondary antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Polyclonal megalin antibodies were a generous gift from Dr. Daniel C.
Biemesderfer, Yale School of Medicine. Antibodies directed towards
NHERF1 and NHERF2 were generous gifts from Dr. Chris Yun, Emory
University School of Medicine. The aquaporin 1 antibody was a giftFig. 1. PTH-TMR labels S1 regions of the proximal tubules, co-localizes with PTH1R-speciﬁ
injected with PTH-TMR (40 nmol/kg) for 5 min, followed by cardiac perfusion and analysis
scopic images of PTH-TMR (red; left panel) and phalloidin-stained actin (green; right panel)
which primarily labels S2 and S3 proximal tubule segments, and PTH-TMR (PTH; red) is sh
analysis of megalin expression. Confocal images displaying localization patterns of megalin (
are shown. D. Five minutes post-ligand injection, proximal tubule images displaying immun
middle panel) and the merge of the two (right panel) are shown. E. Five minutes post-liga
panel) and the merge of the two (right panel) are shown. In the lower left panel, Npt2a
Localization of substrates phosphorylated by PKA (PKA-sub; green) and PTH-TMR (PTH; redfrom Dr. Dennis Brown, Massachusetts General Hospital. The primary
Npt2a antibody was a gift from Dr. Jurg Biber, University of Zurich,
Switzerland. Western Lightning enhanced chemiluminescence reagent
was from Perkin-Elmer (Boston, MA). All general chemicals were pur-
chased from Sigma (Saint Louis, MO).2.2. Immunoﬂuorescence analysis of mouse kidneys
Eight to ten week old C57BL/6 mice were purchased from Charles
River Laboratories (Wilmington, MA) and housed in the MGH animal
facility using accepted ethical guidelines. For experiments aimed at in-
ducing secondary hyperparathyroidism, mice were fed a low-calcium
diet (0.02% calcium from Harlan Teklad, Madison, WI) for ten days
prior to analysis. PTH-TMR was injected subcutaneously at a dose of
40 nmol/kg. After the times indicated, mice were anesthetized and
the left ventricle perfused ﬁrst with 10 to 15 ml of phosphate buffered
saline (PBS), followed by perfusion with freshly prepared 4% formalde-
hyde solution (fromparaformaldehyde) in PBS. Kidneyswere cut on the
sagittal plane and incubated in 4% formaldehyde for 1 to 2 h on ice.
Kidneys were washed in PBS and incubated overnight in 30% sucrose
mixing end-over-end. Frozen sections (8 μ) were prepared by the
Histo Core Facility at MGH using standard procedures.
Frozen sectionswere thawed andwashed in PBS. In order to unmask
epitopes, sections were treated with 0.4% SDS for 4 min depending on
the antibody used, followed by washing in PBS. Samples were blocked
using Super Block from Pierce (Rockford, IL) in PBS containing 0.1%
Triton X-100 (PBST) for 30 min. Primary antibodies, typically at 1:200
dilutions, were incubated on the sections for 3 h at room temperature,
followed by washing in PBST. The appropriate species-speciﬁc second-
ary antibodies labeled with either Alexa ﬂuor-488 or−546 were incu-
bated with the sections for 2 h at room temperature, followed by
washing in PBST. Confocal microscopic images were obtained using a
Radiance 2000 confocal microscopy system (Bio-Rad Laboratories,
Hercules, CA) using LaserSharp 2000. Images were imported into
Adobe Photoshop software as TIFF ﬁles for cropping, merging and
level adjustment.2.3. Isolation of brush-border membranes
Kidney brush-border membranes were prepared as described [20].
Brieﬂy, mice were fed either a normal or a calcium-deﬁcient diet, as
described above, for ten days prior to isolation. Cortices were rapidly
isolated and homogenized with a Polytron homogenizer for 90 s in a
buffer containing 300 mM mannitol, 25 mM HEPES, pH 7.4, 5 mM
EGTA and a protease inhibitor cocktail (Sigma, Saint Louis, MO). While
on ice, 1.3 volumes of water were added to the homogenate, followed
by the addition of MgCl2 to a ﬁnal concentration of 12 mM. Samples
were incubated on ice for 15 min with occasional mixing. Aggregated
membranes were removed by a low-speed spin (3000×g), followed
by isolation of brush-border membranes via a high-speed spin
(30,000×g) of the supernatant. Membrane pellets were resuspended
in a HEPES buffer using a 28-guage needle, protein content was deter-
mined by the Bradford assay and 60 μg loaded onto an SDS-PAGE gel
for PTH1R immunoblot analysis.c antibodies and marks segments that display PTH1R mediated actions. A. Mice were
of frozen sections, as described in the Materials and methods section. Confocal micro-
from the cortex are shown. B. A merged confocal image of aquaporin-1 (Aqp-1; green),
own. C. Mice were injected with PTH-TMR for 15 min, followed by immunoﬂuorescent
green; left panel), PTH-TMR (red; middle panel) and the merge of the two (right panel)
oﬂuorescent analysis of PTH1R localization (green; left panel), PTH-TMR staining (red;
nd injection, localization patterns of Npt2a (green; left panel), PTH-TMR (red; middle
staining in the absence of PTH-TMR labeling on the same kidney section is shown. F.
) is shown in this merged image of the kidney cortex ﬁve minutes post-ligand injection.
Fig. 2. Secondary hyperparathyroidism induced by a low-calcium diet down regulates
the brush-border PTH1R and promotes PTH-TMR/megalin co-localization. A. Mice,
fed either a normal diet (Norm Ca; left panels) or a low-calcium diet (Low Ca; right
panels) for ten days, were subcutaneously injected with PTH-TMR for 5 min prior
to cardiac perfusion and ﬁxation. Confocal images of PTH-TMR labeling (upper
panels) and megalin immunostaining (lower panels) of kidney cortices are shown.
B. Confocal microscopic images of megalin immunostaining (green; left panel),
PTH-TMR labeling (red; middle panel) and merged (left panel) from mice fed a low
calcium diet are shown. C. Kidney brush-border membranes were isolated from
mice fed the normal or low calcium diets and analyzed by immunoblotting with
PTH1R-speciﬁc antibodies, as indicated. The arrow designates the location of the
PTH1R on the blot.
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An adenoviral vector expressing a rhodopsin-tagged ezrin was
generated, as previously described [10]. Early passage LLC-PK1 cells
were seeded in 15 cm dishes and transduced with the ezrin-rho ad-
enovirus. Forty-eight hours post-transduction, cells were extracted
with a solution containing 25 mM HEPES, pH 7.4, 10% glycerol,
150 mM NaCl, 1.0% Triton X-100, 0.1% SDS and protease inhibitor
cocktails (Sigma, Saint Louis, MO). Ezrin-rho was immunopuriﬁed
using rho-tag-speciﬁc 1D4 antibodies (National Cell Culture Center,
Minneapolis, MN) and protein A agarose (Roche, Indianapolis, IN),
followed by elution with the 9 amino acid rho peptide (TETSQVAPA)
at 10 μM for 1 h at room temperature. Ezrin-rhowas cleavedwith re-
combinant calpain protease (EMD Biosciences, Darmstadt, Germany) in
a HEPES buffer supplemented with 1 mM CaCl2 for 30 min at room
temperature. Uncleaved and cleaved ezrin were analyzed using stan-
dard SDS-PAGE and immunoblotting with 1:1000 dilutions of the
CS3145 and 3C12 antibodies, followed by visualization using enhanced
chemiluminescence.
For the analysis of ezrin activation-dependent antibody binding,
enzymatic depletion of phosphatidylinositol-4,5-bisphosphate (PIP2),
which inactivates intracellular ezrin, was employed. Generation of the
membrane-anchored, phosphatidylinositol-4,5-phosphatase (PIPase)
construct was as previously described [21]. HEK293 cells were sparsely
seeded on gelatin-coated chamber slides. Cells were transiently
transfected with ezrin-rho using FuGene 6 (Roche, Indianapolis, IN) in
combination with either LacZ (control) or PIPase. Forty-eight hours
post-transfection, cells werewashed in PBS and ﬁxedwith 4% formalde-
hyde (from paraformaldehyde) in PBS. Cells were immunostained with
either CS3145 or 3C12 ezrin antibodies and secondary antibodies
labeledwith Alexaﬂuor-488, followed by confocalmicroscopic analysis,
as described above.
2.5. Data analysis
A minimum of three independent experiments was performed
for each condition. Representative confocal microscopic images are
presented.
3. Results
3.1. PTH-TMR marks the location of the PTH1R in PCTs
Localization of the PTH1R is hampered by the lack of quality anti-
bodies capable of detecting receptors expressed in native tissues using
immunoﬂuorescence-based analyses. To overcome this limitation,
PTH was labeled with the ﬂuorescent dye, tetramethylrhodamine
(PTH-TMR), which displays a remarkable level of sensitivity and speci-
ﬁcity for the detection of the PTH1R in cell culture-based assays [21,22].
Analysis of the PTH-TMR staining pattern in the mouse kidney was un-
dertaken. As shown in Fig. 1A, PTH-TMR readily localizes to the luminal
surface of PCT within vesicle-like structures. PCT segments were easily
identiﬁed by the thick, actin-rich brush-borders (Fig. 1B). PTH-TMR
staining is also evident in parietal cell layers of the glomeruli (Fig. 1A).
PTH-TMR-labeled segments were generally localized near glomeruli
and did not co-localize with aquaporin1, which is predominantly
expressed in S2/S3 segments (Fig. 1B), demonstrating that S1 segments
of the PCT are the primary binding sites for the ligand post subcutane-
ous injection.
Although PTH-TMR staining on the luminal surfaces is consistent
with previous studies localizing the PTH1R to the PCT brush-border,
as described in the Introduction, experiments were performed to ver-
ify that the ﬂuorescent ligand was in fact marking the location of the
receptor. Megalin or LRP2 is a multi-ligand, endocytotic receptor that
binds to PTH with micromolar afﬁnity in vitro [23]. Although some
general overlapping staining exists between megalin and PTH-TMR,the unique, internalized vesicular staining pattern generated by the
ligand does not co-localize with the megalin antibody (Fig. 1C), indi-
cating that the PTH-TMR is likely labeling the PTH1R. Although
PTH-TMR co-endocytosis with megalin cannot be fully ruled out for
all vesicles. Consistent with this data, immunostaining with a com-
mercially available PTH1R antibody and PTH-TMR co-localize to the
apical membranes of the PCT (Fig. 1D), albeit with a high degree of
background staining from the antibody.
Additional evidence in support of PTH-TMR/PTH1R co-localization
would be to demonstrate a correlative functional effect. As noted earlier,
PTH mediates the acute down regulation of the type IIa sodium-
phosphate co-transporter (NPT2a) in the PCT. During the initial stages
of this process, PTH-TMR directly co-localizes with NPT2a at the base
of the microvilli (Fig. 1E), revealing that the PTH1R co-internalizes
2247J. Guo et al. / Biochimica et Biophysica Acta 1823 (2012) 2243–2253with the regulated transporter. Furthermore, the PTH1R readily couples
to the stimulatory G protein (Gs), leading to the robust generation of
cAMP and activation of PKA. As shown in Fig. 1F, PTH-TMR-labeled
tubular segments display a marked increase in staining with PKA sub-
strate antibodies when compared to segments lacking the ligand, dem-
onstrating a strong correlation between the presence of ligand and
receptor activation.
Further experiments were done to verify that PTH-TMR is marking
the PTH1R. When mice are placed on a calcium-deﬁcient diet, circulat-
ing levels of PTH markedly increase, an adaptive process that leads to
the maintenance of blood calcium levels through bone resorption and
enhanced tubular reabsorption in the kidney. In the hyperparathryoidFig. 3. Various effectors of G protein coupled receptors are prominently expressed in the bru
(B) Gαs, (C) Gαi3, (D) Gαq/11 and (E) PLCβ1 in proximal tubule segments using confocal mstate, PTH-TMR labeling is markedly reduced and limited primarily to
the parietal cell layer of Bowman's capsule (Fig. 2A). General megalin
staining is largely unaffected by the low calcium diet when compared
tomice fed a normal diet (Fig. 2A). Notably, PTH-TMR labeling of the pa-
rietal cell layer and immediate tubular sections display co-localization
with megalin (Fig. 2B). Furthermore, PTH1R expression within
brush-border membranes is markedly decreased in mice fed the
low calcium diet when compared to normal diets, suggesting that
the receptor is chronically internalized in the hyperparathyroid
state (Fig. 2C) and thus unable to bind to the PTH-TMR probe.
As shown in Fig. 3, many components of the heterotrimeric G
protein-based signaling machinery are expressed on the luminalsh-border membranes of proximal tubules. Immunoﬂuorescent analyses of (A) panGβ,
icroscopy are shown.
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ﬁndings demonstrate that essential components of GPCR signaling are
present in the brush-border compartment of the PCT, overlapping
PTH-TMR binding. It is unclear, however, if these components are
directly associated with the scaffold complex. Combined with the data
noted above, these ﬁndings strongly indicate that PTH-TMR is binding
to and marking the location of the apically expressed PTH1R within
the PCT and ligand in the primary ﬁltrate is functionally active.
3.2. Localization of NHERF1, NHERF2 and ezrin in the kidney cortex
With this new analytical tool, PTH1R co-localization with the
ezrin-NHERF-based scaffold complex was assessed. First, immunological
expression analysis of these scaffold proteins was examined using the
available antibody reagents in the cortex of the mouse kidney. Ezrin
and NHERF1 are predominantly expressed in the brush-borders of the
PCT, as shown in Fig. 4A and B, respectively. Ezrin is also expressed in
the podocytes of the glomerulus, albeit to a lesser extent (data not
shown). NHERF2 is abundantly expressed in the podocytes of the glo-
merulus and in the endothelial cells of the peritubular capillaries and
major blood vessels, and to a lesser extent in the brush-border of the
PCT (Fig. 4C). As shown in Fig. 4D, expression patterns for ezrin and
NHERF1 directly overlap in the brush-border of the PCT. Conversely,Fig. 4. Localization patterns of the ezrin-NHERF scaffold complexes in the proximal tubules o
(A) ezrin (CS3145 polyclonal), (B) NHERF1 and (C) NHERF2 in the kidney cortex are shown
with ezrin (3C12 monoclonal, red; middle panels) and the merged images (right panels) aNHERF2 appears to be expressed at the base of the PCT microvilli and
only partially co-localizes with ezrin (Fig. 4E). In general, these localiza-
tion patterns are consistent with previously published ﬁndings [18,19].
3.3. Co-localization of PTH1R/PTH-TMR with the ezrin-NHERF scaffold
As previously mentioned, both NHERF1 and 2 interact with the
PTH1R in vitro and within cell models via a PDZ domain-mediated
process. To assess these interactions in vivo, localization patterns of
the PTH-TMR/PTH1R with the NHERF scaffold proteins in the PCT
were analyzed. Two-time points were used post PTH-TMR injection
at 5 and 15 min. A caveat exists in that these time points are relative
due to the post-injection processing of the mice, including the process
of cardiac perfusion with PBS and formaldehyde, which adds an addi-
tional 10 to 15 min to the time course prior to arrest via ﬁxation. At
the 5 min time point, PTH-TMR appears in vesicle-like structures
lined up close to the membrane, while at 15 min PTH-TMR labeled
vesicles are generally further from the membrane in a more scattered
pattern (Fig. 5A). We interpret these patterns to represent early and
latter stages of PTH1R endocytosis. At the 5-min time point, PTH-
TMR-labeled vesicles partially co-localize with NHERF1 at the inner-
most portion of the stain, while at 15 min the internalized vesicles
do not co-localize with NHERF1 (Fig. 5A). Regarding NHERF2,f the kidney. Confocal microscopic images of immunoﬂuorescent localization analysis of
. Co-localizations of (D) NHERF1 (green; left panel) and (E) NHERF2 (green; left panel)
re shown.
Fig. 5. Co-localization of PTH-TMR and NHERF proteins in the PCT. Mice were injected with PTH-TMR for either 5 (5 m) or 15 (15 m) minutes, as indicated. PTH-TMR staining (red;
middle panels) and localization patterns for either (A) NHERF1 or (B) NHERF2 (green; left panels), as indicated, were analyzed using immunoﬂuorescence techniques and confocal
microscopy within labeled proximal tubular segments. Merged images are shown in right panels.
2249J. Guo et al. / Biochimica et Biophysica Acta 1823 (2012) 2243–2253PTH-TMR co-localizes with this scaffold protein in a region that likely
represents the base of the microvilli (Fig. 5B). Similar to NHERF1,
internalized vesicles do not readily co-localize with NHERF2 in the
latter, 15-min time point (Fig. 5B). PTH-TMR co-localization with
ezrin was then undertaken.
As previously mentioned, the PTH1R interacts with ezrin through
a juxtamembrane-binding domain on the C-terminal tail of the recep-
tor. Analysis of the PTH-TMR/ezrin co-localization patterns at the 5
and 15-min time points revealed an unexpected effect. At 5 min,
PTH-TMR-labeled vesicles directly co-localize with a small fraction
of the ezrin protein (Fig. 6A); however, the bulk of the ezrin protein
appears absent. As shown in the same microscopic ﬁeld of Fig. 6A,
marked reductions of total ezrin staining is evident in PTH-TMR-
stained PCT segments, in contrast, those segment lacking the ligand
display abundant levels of immunostained ezrin. At 15 min, the
PTH-TMR-labeled vesicles have completely dissociated from ezrin
and the bulk of the ezrin protein is now detectable (Fig. 6B). A possi-
ble interpretation of these results is that PTH induces a conformation-
al change that has rendered the bulk of ezrin undetectable by the
polyclonal, CS3145 antibody and that this effect is rapidly reversed
by the 15-min time point. To investigate this possibility, a second
ezrin antibody was used. As shown in Fig. 6B, a monoclonal ezrin
antibody (3C12) readily detects the bulk of the ezrin protein inPTH-TMR-labeled segments at the 5-min time point, conﬁrming that
ezrin is still present in the same PCT segments and that this antibody
can detect ezrin regardless of the PTH-elicited alternations in immu-
noreactivity. Staining of the basement membrane, shown in Fig. 6B,
occurs in the absence of the primary antibody and is due to the use
of anti-mouse IgG secondary antibodies in the same species.
Through intramolecular interactions between amino- and carboxy-
terminal domains, ezrin can assume a closed, inactive conﬁrmation,
yielding a masked FERM domain incapable of binding to membrane-
bound proteins [24]. A combination of phosphorylation at Thr567 and
binding to phosphatidylinositol-4,5-bisphosphate (PIP2), generates an
open, active form of ezrin [25,26]. To identify the general location of
the epitope used to develop the polyclonal, CS3145 antibody, recombi-
nant ezrin was puriﬁed and cleaved with the calpain protease, which
generates two fragments of 55 and 15 kDa (Fig. 7A) [27]. As shown in
Fig. 7B, CS3145 antibodies recognize the 55 kDa fragment, revealing
an epitope that is likely within the FERM domain. The monoclonal anti-
body (3C12) detects the 15 kDa fragment, conﬁrming the presence of a
C-terminal epitope (Fig. 7B). Based on the hypothesis put forth from
data in Fig. 6, we predict that the polyclonal, CS3145 antibody can
only recognize the active, open conformation of ezrin and that the
monoclonal, 3C12 antibody can bind to both active and inactive confor-
mations. When transiently transfected into HEK293 cells, ezrin is
Fig. 6. Time-dependent co-localizations between PTH-TMR and ezrin reveal possible ligand-induced conformational changes. Ezrin localization patterns using (A and B) polyclonal
CS3145 antibodies or (B) monoclonal 3C12 antibodies (green; left panels), as indicated, were analyzed in tubular segments stained with PTH-TMR (red; middle panels) for the
times indicated, 5 or 15 min (5 m or 15 m). Confocal microscopic images and merged images (right panels) are shown.
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tion pattern consistentwith the active conformation of this scaffold pro-
tein. Expectedly, both antibodies readily detect this active form of ezrin
when co-expressed with the LacZ control protein, as shown in Fig. 7C
and D. Hydrolysis of PIP2 using a phosphatidylinositol-4,5-phosphatase
(PIPase) inactivates ezrin when co-expressed in these cells [21]. As
shown in Fig. 7C, co-transfection of ezrin with PIPase markedly reduces
immunoﬂuorescent detection using the CS3145 antibody. In contrast,
the 3C12 antibody readily detects the cytoplasmic, inactive form of
ezrin when co-expressed with the PIPase enzyme (Fig. 7D), as demon-
strated by the presence of nuclear shadows in the image.
4. Discussion
It is well established that scaffold proteins assemble multi-faceted
complexes that facilitate physiological processes by limiting diffusion of
essential components [28–30]. PTH acutely induces hypophosphatemia
through regulated endocytosis of NPT2a, thus providing a model
process to study non-genomic actions of this hormone. Importantly,
both the PTH1R and NPT2a appear to be components of the ezrin-
NHERF-based scaffold located on the brush-border of the PCT, thus
identifying a likely signaling complex directed at regulating the
reabsorption of phosphate ions in vivo. To date, most reports examining
PTH1R/scaffold interactions have relied on the use of in vitro models.
With the aid of the PTH-TMR probe, the current research analyzes the
in vivo assembly of these complexes in the proximal tubule of the
mouse kidney.
Due to the general poor quality of PTH1R antibodies, effective
analysis of receptor localization in native tissues has been limited.
We believe that the ﬂuorescent PTH-TMR probe is an effective,
novel tool to investigate PTH1R dynamics for several reasons. First
of all, PTH-TMR binding displays an impressive degree of speciﬁcity
when using cell culture models in the absence or presence of the
PTH1R [21,22]. Second, PTH-TMR luminal staining of the PCT is con-
sistent with several reports that demonstrate apical localization ofthe PTH1R [4–7,23]. Most of these reports have used the Covance
PTH1R antibody. Although the background is high for this antibody in
our hands, the unique patterns generated by the PTH-TMR-labeled ves-
icles clearly overlap the immunostaining pattern displayed by this anti-
body, indicating that this ligand probe likelymarks the receptor (Fig. 1).
Furthermore, the clathrin adapter, AP1B, binds to the PTH1R and directs
basolateral expression in polarized cell models; however, the PCT does
not express this adapter, resulting in apical expression of the receptor,
as demonstrated in models of MDCK cells [31]. This ﬁnding and apical
localization of many components associated with GPCR signaling,
shown herein and by others [32–34], lend credence to the assertion
that PTH within the primary ﬁltrate activates apical receptors. Third,
megalin, a scavenger receptor that binds PTH with micromolar afﬁnity
[23], fails to readily co-localizewith PTH-TMR-labeled, cytoplasmic ves-
icles. Consistent with this ﬁnding, Bacic et al. [35] failed to detect any
PTH-induced megalin endocytosis in mouse PCT upon injection of
unlabeled ligand. Lastly, early PCT segments labeled with PTH-TMR dis-
play functional effects that are consistent with PTH1R activation, such
asmarked increases in staining of PKA-substrate antibodies and robust,
acute internalization of NPT2a. Notably, Picard et al. [36] reported that
PTH-elicited NPT2a internalization is strongest in the S1 segments of
the PCT, directly overlapping the primary location of PTH-TMR binding.
Combined, these ﬁndings reveal that acute effects of a bolus PTH injec-
tion in the kidney occur immediately after ﬁltration through the glo-
meruli, accessing apical PTH1R sub-populations.
Despite the obvious utility, limitations for the use of the PTH-TMR
probe exist. Upon cloning of the PTH1R gene, probing of standard
multi-tissue Northern blots revealed that the receptor is markedly
expressed in the kidney when compared to the low level expression
found in most tissues [37]. This ﬁnding, combined with the PCT as a
primary target, supports the contention that the PTH1R is expressed
to a level in this tissue that allows for detection using the PTH-TMR
ligand. Conversely, the absence of staining is likely due to the fact
that PTH1R expression levels in other regions of the kidney or other
tissues, such as bone (unpublished observations), are probably
Fig. 7. The ezrin polyclonal antibody appears to detect only the active conformation,while
the monoclonal antibody binds to ezrin regardless of the activation status. A. Schematic
depicting the calpain cleavage site on ezrin, which yields 55 and 15 kDa proteolytic frag-
ments. B. Ezrin containing a C-terminal rho-tagwas expressed and puriﬁed as described in
theMaterials andmethods section. Ezrinwas treated in the absence or presence of calpain
protease, as indicated, for 30 min at room temperature, followed by immunoblot analysis
using either the polyclonal (CS3145; left panel) or the monoclonal (3C12; right panel)
antibodies. Representative immunoblots of the ezrin epitopes are shown. C and D. HEK
cells were transiently transfected with ezrin and either LacZ (left panels) or PIPase
(right panels), as indicated. Confocal microscopic images of ezrin expression patterns using
either the polyclonal CS3145 (C) or the monoclonal 3C12 (D) antibodies are shown.
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probe's usefulness to the PCT. In other words, the lack of PTH-TMR
staining does not necessarily indicate the absence of receptor expres-
sion. Lastly, it is conceivable that the PTH-TMR ligand is not directlymarking the PTH1R, but to some unknown receptor. If true, then it
is possible that this probe is still an indicator of those segments
expressing the PTH1R due to the functional correlation demonstrated
with the PKA-substrate antibodies, NPT2a internalization and appar-
ent conformational changes in ezrin.
The existence of two PTH receptors, the PTH1R and megalin, with-
in the PCT puts forth a compelling paradigm, one high afﬁnity-low ca-
pacity and one low afﬁnity-high capacity, respectively. Stressing mice
with a low calcium diet reveals markedly reduced PTH-TMR labeling,
an effect that correlates with a loss of PTH1R protein in brush-border
membranes and no apparent effect on overall megalin expression.
However, it is also possible that chronic PTH stimulation may induce
changes in the PTH1R that lower ligand-binding afﬁnities; thus
reducing PTH-TMR staining. Notably, PTH-TMR labeling that does
exist on the low calcium diet readily co-localizes with megalin in
the parietal cell layer and very early PCT segments. Upon receptor in-
ternalization in the hyperparathyroid hormone state, PTH-TMR binds
to megalin, but only immediately after entering the tubules upon ﬁl-
tration through the glomeruli, which suggests that the initial concen-
tration of ligand is high enough to interact with this scavenger. Under
normal conditions, however, dilution of PTH-TMR as it transits down
the tubule maintains a high enough concentration capable of binding
to the high afﬁnity PTH1R but not the low afﬁnity megalin receptor.
These ﬁndings strongly suggest that PTH-TMR is labeling the PTH1R
primarily with a lesser amount of binding to megalin.
Through an atypical, C-terminal PDZ interaction motif, the PTH1R
readily interacts with both NHERF1 and 2 in vitro, in cells and in kidney
extracts, as determined by co-immunoprecipitation [11,12]. Within in
the PCT, NHERF1 is abundantly expressed within the microvilli,
whereas NHERF2 is predominantly localized to the base of themicro-
villi, patterns that are consistent with previously published ﬁndings
[18]. In the early time points, PTH-TMR binding localizes to the base
of the microvilli primarily overlapping NHERF2; however, one can-
not rule out the possibility that ligand initiates a rapid relocalization
from the microvilli to the base. In general, the current ﬁndings reveal
that as endocytosis proceeds, the PTH1R likely dissociates from the
apical scaffold complex, which is consistent with data published by
Friedman and co-workers using transformed cell lines [38]. Further-
more, our data are consistent with those of Weinman and co-workers
[39], revealing that NHERF1 dissociates from both NPT2a and possibly
the PTH1R upon endocytosis via a process that likely involves phos-
phorylation of NHERF1.
From our earlier studies [10,21], it was fully anticipated that the
PTH-TMR-labeled luminal surface of the PCT would readily localize
with ezrin, a scaffold that exists in the brush-border of this segment.
It is well established that ERM proteins, such as ezrin, possess intrin-
sic, auto-regulatory activation mechanisms mediated through confor-
mational changes induced by intramolecular interactions between
the amino-terminal FERM domain and a carboxy-terminal domain
[24,40]. Our ﬁndings reveal that the CS3145 antibody, which pos-
sesses an amino-terminal epitope, is unable to recognize the inactive,
closed form of ezrin, a mechanism that is likely due to epitope
masking by the carboxy-terminal domain upon ﬁxation. Therefore,
the inability of this antibody to detect the bulk of ezrin in PTH-TMR
stained segments strongly suggests that this scaffold is a target for
downstream signaling processes mediated by the PTH1R. In contrast,
the carboxy-terminal epitope of the monoclonal, 3C12 antibody is not
masked and thus capable of detecting both active and inactive forms
of ezrin. Consequently, the 3C12 antibody readily detects the bulk of
ezrin at the 5-min time point, as well as ezrin sub-population associ-
ated with the PTH-TMR probe. Notably, these ﬁndings strongly sug-
gest that the PTH1R, marked with the ligand probe, interacts with
ezrin and that PTH signaling induces acute conformational changes
in the bulk of ezrin.
With respect to the apparent PTH-induced conformational
changes in ezrin, two key ﬁndings exist. First, the abundant levels of
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levels of the PTH1R. Therefore, one would assume that only a small
fraction of ezrin would co-localize with the PTH1R. This contention
is supported by the fact that low levels of ezrin readily co-localize
with the PTH-TMR probe during the initial stages of endocytosis. Con-
sidering the high background of the receptor-speciﬁc antibodies,
co-immunolocalization of these low levels of ezrin, using the mono-
clonal antibodies, and the PTH1R would be difﬁcult. This distinct
co-localization also reveals that PTH-TMR does not interfere with
ezrin immunolocalization. Furthermore, the ability to detect PTH-TMR
co-localization with both ezrin antibodies within the nascent vesicles
suggests that ezrin is in the active, open conformation when bound to
the PTH1R. This assertion is consistent with our previous ﬁndings dem-
onstrating that the PTH1R C-tail binding to the FERM domain is
inhibited by the carboxy-terminal half of ezrin [10], revealing preferen-
tial binding to the open, active form. Other established ezrin binding
partners also preferentially interact with the active form [41]. Second,
the apparent PTH-elicited changes in the conformation of the bulk of
ezrin likely arise from PTH1R activation and the inherent signal ampli-
ﬁcation associated with second messenger production and stimulation
of downstream effector enzymes, such as kinases, that possess high
levels of processivity and substrate turnover.
Both cAMP/PKA and PLC/PKC are activated by the PTH1R, pathways
that likely target the ezrin scaffold complex. With the use of kinase-
speciﬁc substrate antibodies, Nashiki et al. [42] demonstrated that
PTH invokes both PKA- and PKC-dependent phosphorylation of
ezrin in opossum kidney cells. Yao and co-workers [43] reported
that PKA-mediated phosphorylation of ezrin on Ser66 mediates api-
cal cytoskeleton remodeling associated with gastric parietal cell acti-
vation. Furthermore, ezrin has been shown to be an AKAP (A-kinase
anchoring protein) [44] and AKAP79 directly interacts with NTP2a in
OK cells [45], thus providing additional levels of regulation that is
possiblymediated by the scaffold complex. Transient conformational
changes in ezrin could also arise from local depletion of PIP2 via ac-
tivation of PLCβ. It is well established that PIP2 is required to main-
tain the active form of ezrin [26,46,47], as conﬁrmed by the effect
of the PIPase shown in Fig. 7. Certainly, PTH-elicited depletion of PIP2
is expected to be far less extensive than the membrane-anchored
PIPase, an effect that is consistent with the transient nature of the
conformational change in ezrin demonstrated by the PTH-TMR ligand.
Considering that ezrin is an intrinsic component of brush-border mem-
branes, the ability of PTH to modify cytoskeletal structures in primary
proximal tubule cells [48], LLC-PK1 cells [49] and in osteoblasts [50]
establishes a possible functional link to the dynamic regulation of this
scaffold protein.
The ability to readily identify PTH1R localization using the PTH-TMR
probe is a novel technique that will allow for the better understanding
of receptor function within the PCT target tissue, especially signals
emitted from the apical sub-population. With this novel tool in hand,
it is readily apparent that following an injection of a bolus of hormone,
PTH is readily ﬁltered through the glomeruli and accesses receptors lo-
cated on the luminal surface of the PCT. Furthermore, the brush-border
membrane compartment not only provides the ezrin-based scaffold
complex, but also contains a full complement of G proteins and relat-
ed effector molecules that establish a fully functional PTH/PTH1R
signalsome. Future directions include analyzing the nature of the
PTH-induced conformational change in ezrin and possible mecha-
nisms associated with the down regulation of NPT2a.
5. Conclusions
1 The ﬂuorescent PTH-TMR probe, upon subcutaneous injection, labels
the luminal surface of early (S1) segments of the kidney proximal
convoluted tubule that co-localize with PTH1R-speciﬁc antibodies
but not readily with megalin antibodies, thus marking the PTH1R.2 Activation of PKA and internalization of NPT2a are evident functional
effects that correspond to PTH-TMR labeled segments, demonstrating
a fully active PTH1R.
3 Heterotrimeric G proteins and effector molecules associated with
GPCRs distinctly localize to the brush-border surface of the proximal
tubule.
4 During the initial stages of ligand binding, PTH-TMR/PTH1R co-
localizes with a sub-population of ezrin and mediates a conforma-
tional change in the bulk of uncomplexed ezrin consistent with
inactivation of the scaffold complex.
5 As endocytosis progresses, the PTH-TMR/PTH1R complex dissociates
from the ezrin-NHERF scaffold.Acknowledgements
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